Baseline demographics and physiological data of study subjects
| PHT (n=15) | Controls (n=11) | p Value | |
|---|---|---|---|
| Age, years | 61±12 | 51±21 | 0.20 |
| Male, n | 6 | 7 | 0.43 |
| BMI, kg/m2 | 29±6 | 26±7 | 0.31 |
| Aetiology | PAH:10 (IPAH: 8, CTD-PAH:2) CTEPH:5 | ||
| Invasive haemodynamics* | |||
| sPAP, mm Hg | 65±17 | ||
| dPAP, mm Hg | 23±8 | ||
| mPAP, mm Hg | 40±10 | ||
| PCWP, mm Hg | 10±3 | ||
| RAP, mm Hg | 7±5 | ||
| Echocardiographic parameters | |||
| sPAP, mm Hg | 72±23 | ||
| TAPSE, cm | 1.8±0.4 | ||
| Right atrial area, cm2 | 26±8 | ||
| Pericardial effusion, % | 13% | ||
| Lung function parameters | |||
| FEV1, % predicted | 87±13 | ||
| FVC, % predicted | 97±13 | ||
| FEV1/FVC ratio | 73±7 | ||
| DLCO, % predicted | 61±14 | ||
| TLC, % predicted | 96±10 | ||
| Functional capacity | |||
| 6 min walk distance, m | 429±137 | ||
| WHO functional class, n | I: 1 II: 6 III: 8 | ||
| Therapy | |||
| Endothelin antagonists | 73% | ||
| Phosphodiesteriase-5 inhibitors | 53% | ||
| Prostanoids | 13% | ||
| Combination therapy | 40% | ||
*Pulmonary haemodynamics are from right heart catheterisation at time of initial diagnosis.
BMI, body mass index; CTD-PAH, connective tissue associated PAH; CTEPH, chronic thromboembolic pulmonary hypertension; DLCO, diffusing capacity for carbon monoxide; dPAP, diastolic pulmonary artery pressure; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; IPAH, idiopathic pulmonary arterial hypertension; mPAP, mean pulmonary artery pressure; PAH, pulmonary arterial hypertension; PCWP, pulmonary capillary wedge pressure; PHT, pulmonary hypertension; RAP, right atrial pressure; sPAP, systolic pulmonary artery pressure; TAPSE, tricuspid annular plane systolic excursion; TLC, total lung capacity.